Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 16/20 | 0.81 |
| ▸ | BCHE | P06276 | 10/20 | 0.76 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9513227 | 0.98 | ACHE (0.79) | ACHEBCHEPRMT6 | |
| SCHEMBL10358445 | 0.85 | ACHE (0.83) | ACHEBCHEPRMT6 | |
| SCHEMBL9630173 | 0.83 | ACHE (0.79) | ACHEBCHEPRMT6 | |
| SCHEMBL10358390 | 0.81 | ACHE (0.96) | ACHEBCHEPRMT6 | |
| SCHEMBL2458150 | 0.81 | ACHE (0.74) | ACHEBCHEPRMT6 | |
| SCHEMBL11178364 | 0.80 | ACHE (0.80) | ACHEBCHEPRMT6 | |
| SCHEMBL10910254 | 0.80 | ACHE (0.80) | ACHEBCHEPRMT6 | |
| SCHEMBL10358388 | 0.80 | ACHE (0.86) | ACHEBCHEPRMT6 | |
| SCHEMBL7995056 | 0.80 | PRMT6 (1.00) | ACHEBCHEPRMT6 | |
| SCHEMBL10358434 | 0.80 | ACHE (0.80) | ACHEBCHEPRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| EP-0269315-A2 | Amine production | NIPPON SHOKUBAI CO., LTD. (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | ACHE 3795/4885BCHE 3271/4885PRMT6 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.